Alpine Immune Sciences, Inc.
NASDAQ:ALPN
Overview | Financials
Company Name | Alpine Immune Sciences, Inc. |
Symbol | ALPN |
Currency | USD |
Price | 64.97 |
Market Cap | 4,456,779,835 |
Dividend Yield | 0% |
52-week-range | 8.33 - 65 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Mitchell H. Gold M.D. |
Website | https://www.alpineimmunesciences.com |
An error occurred while fetching data.
About Alpine Immune Sciences, Inc.
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD